Edgewise Therapeutics Inc (EWTX)
31.98
+0.03
(+0.09%)
USD |
NASDAQ |
Nov 21, 16:00
32.01
+0.03
(+0.09%)
After-Hours: 20:00
Edgewise Therapeutics Enterprise Value: 2.536B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.536B |
| November 20, 2024 | 2.533B |
| November 19, 2024 | 2.491B |
| November 18, 2024 | 2.423B |
| November 15, 2024 | 2.484B |
| November 14, 2024 | 2.620B |
| November 13, 2024 | 2.657B |
| November 12, 2024 | 2.840B |
| November 11, 2024 | 2.853B |
| November 08, 2024 | 2.952B |
| November 07, 2024 | 2.862B |
| November 06, 2024 | 2.975B |
| November 05, 2024 | 2.911B |
| November 04, 2024 | 2.772B |
| November 01, 2024 | 2.727B |
| October 31, 2024 | 2.686B |
| October 30, 2024 | 2.653B |
| October 29, 2024 | 2.760B |
| October 28, 2024 | 2.721B |
| October 25, 2024 | 2.810B |
| October 24, 2024 | 2.776B |
| October 23, 2024 | 2.794B |
| October 22, 2024 | 2.757B |
| October 21, 2024 | 2.798B |
| October 18, 2024 | 2.866B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.860B |
| October 16, 2024 | 2.815B |
| October 15, 2024 | 2.622B |
| October 14, 2024 | 2.512B |
| October 11, 2024 | 2.521B |
| October 10, 2024 | 2.339B |
| October 09, 2024 | 2.371B |
| October 08, 2024 | 2.197B |
| October 07, 2024 | 2.114B |
| October 04, 2024 | 2.189B |
| October 03, 2024 | 2.022B |
| October 02, 2024 | 2.081B |
| October 01, 2024 | 2.086B |
| September 30, 2024 | 2.027B |
| September 27, 2024 | 1.935B |
| September 26, 2024 | 1.925B |
| September 25, 2024 | 1.914B |
| September 24, 2024 | 1.919B |
| September 23, 2024 | 1.972B |
| September 20, 2024 | 2.140B |
| September 19, 2024 | 2.255B |
| September 18, 2024 | 1.276B |
| September 17, 2024 | 1.183B |
| September 16, 2024 | 1.069B |
| September 13, 2024 | 1.254B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
15.26M
Minimum
May 25 2022
2.975B
Maximum
Nov 06 2024
623.44M
Average
343.40M
Median
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 2.077B |
| Cytokinetics Inc | 5.270B |
| Vanda Pharmaceuticals Inc | -88.22M |
| Vertex Pharmaceuticals Inc | 109.46B |
| Sarepta Therapeutics Inc | 10.58B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.13M |
| Total Expenses (Quarterly) | 40.43M |
| EPS Diluted (Quarterly) | -0.36 |
| Earnings Yield | -4.68% |